DataMEDS AI Releases CEO Letter
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
DataMEDS AI (MEDS) outlined its fourth-quarter 2026 business priorities in a shareholder letter focused on patient management and healthcare data. The company plans to use its pharmacy, laboratory and telemedicine operations to support research and develop new intellectual property. A Florida-based health maintenance organization is working with DataMEDS on its Health Lives Here initiative, initially focused on GLP-1 patient management. The recent Helomics acquisition adds to its healthcare operations.
DataMEDS has 5,724,857 common shares outstanding, including 2,745,900 deposited at DTCC and available for trading. Holders of approximately 1,333,930 shares have agreed not to sell into the market for at least 90 days from November 16, 2026. Separately, 80,826 cash warrants are eligible for exercise into freely trading common shares at a fixed $35.00 per share.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointA Florida-based HMO is working with DataMEDS on patient management through Health Lives Here.
- Moderate pointThe completed Helomics acquisition adds a clinical molecular diagnostics laboratory to DataMEDS.
- Minor point. Forward-looking: it has not happened yet and may not happen.DataMEDS plans to increase patient flow to support profitable research and development and expects new intellectual property.
- Minor pointApproximately 1,333,930 shares are locked against market sales for at least 90 days from November 16, 2026.
Negative
- Minor point. Forward-looking: it has not happened yet and may not happen.80,826 cash warrants exercisable at $35.00 per share could add freely trading common shares.
News Explained
The letter says no debt, preferred equity, or warrant securities are currently eligible to convert into freely trading common shares; 80,826 cash warrants remain separately exercisable into such shares at $35 each, making exercise—not conversion—the disclosed warrant route to additional shares.
Key Figures
- Common shares outstanding
- 5,724,857 common shares
- As stated in the CEO letter
- Shares available for trading
- 2,745,900 common shares
- Deposited in DTCC and available for trading
- Shares under lock-up
- approximately 1,333,930 common shares
- Lock-up agreements preclude sale for at least 90 days from the release date
- Lock-up period
- at least 90 days
- From the release date
- Cash warrants outstanding
- 80,826 warrants
- Eligible for exercise into free-trading common shares
- Warrant exercise price
- $35.00 per share
- Fixed exercise price for cash warrants
Previous AI Reports
-
Licensed exclusive U.S. rights to REBOOT's GLP-1 care platform with revenue sharing.
-
Signed a non-binding MOU for Health Lives Here deployment with a Florida-based HMO.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
glp-1 medical
health maintenance organization medical
smart contracts technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
TAMPA, FL / ACCESS Newswire / November 16, 2026 / DataMeds AI, Inc. ("DataMeds SI," "DataMEDS" or("DataMEDS" or the "Company") (NASDAQ:MEDS), a healthcare company that integrates its health information technology and physical infrastructure with its EinsteinRx™ artificial intelligence platform and PharmacyChain™ blockchain-enabled smart contracts platform, today provided a fourth quarter 2026 corporate outlook from its Interim Co-CEO Gerald Commissiong:
"The reality is healthcare in America is broken. To fix it, the focus must go back towards helping the patient, insured or uninsured, who ends up subsidizing the costs. Our business model is rooted in cutting out the middleman so that the payor not only pays a fair price, but more importantly receives beneficial health outcomes as a result. DataMEDS' objective is to narrow the arbitrage between what you are paying for and what you are getting.
To accomplish this daunting task in the face of heavily entrenched and overcompensated stakeholders, we must leverage patients' data to rein in the army of middlemen gouging the industry. Healthcare profits leverage user data to predict future outcomes. To the extent we can do that efficiently, initially in GLP-1 patient management - one of the most expensive pockets of the healthcare ecosystem - we believe we can simultaneously improve outcomes while reducing costs by improving regimen compliance, managing the process of titrating up as therapy is initiated and titrating down as the need for therapeutic intervention lessens, by seamlessly helping to improve patient behavior and providing the right support products at the right time to help manage side effects and helping physicians more efficiently monitor their patients leveraging our technology and intellectual property assets. This is exactly why a Florida-based Health Maintenance Organization (HMO) decided to work with DataMEDS around our Health Lives Here initiative to implement a formulaic process around helping their members manage their health journey. To the extent that we are successful in providing insights that prove useful and deliver better outcomes, lower costs or both, we will have proven a very scalable business model that will allow us to capture more and more institutional payors that see tremendous potential value in our approach and understand that trying to achieve this objective using competitors' platforms violates our healthcare technology intellectual property.
Our physical healthcare infrastructure, which leverages our own pharmacy, lab and telemedicine platforms together with our proprietary independent pharmacy network, allows us to view the different aspects of the healthcare journey through a common lens that creates synergistic revenue streams with each patient interaction. This reduces our reliance on achieving maximum per interaction revenue to instead focus on long-term repeat customers that view our services as a better alternative to their current treatment options, and less risky from an intellectual property litigation standpoint.
The recent acquisition of Helomics underscores our vision to improve outcomes while reducing costs. Cancer, as one of the most devastating health diagnoses a human can receive, is simultaneously one of the most profitable healthcare industries. This type of misaligned incentive structure is what we are seeking to counter through the consolidation of health data, use of artificial intelligence, and quantification of the benefit of various outcomes measurements to fortify the resilience of the artificial intelligence decision making process for the benefit of patients and payors.
To accomplish this objective for the benefit of shareholders, we must create synergies using approaches that may appear disjointed at first glance. For example, we must conduct research and development (R&D), however we must do so profitably by increasing patient flow through our healthcare delivery portals and compliantly leveraging that patient base to create new data inputs that can be used to deliver measurable benefit outputs in the future. We know that most patients are willing to allow their data to be used in a de-identified way to help improve treatment paradigms. In doing so, we expect to create new intellectual property that will add to our proprietary positioning.
As we work to complete the turnaround that began in the second quarter, we are focused on delivering value to patients, organizations that manage patients and shareholders. We would like to thank our stakeholders for their engagement as we work through this process to deliver tangible solutions for the healthcare community."
Menlo Ventures recently published a report entitled "2026: The State of AI in Healthcare" that details current artificial intelligence trends within the healthcare industry. The report notes:
- Healthcare is AI's biggest vertical market; spend grew 2.5x to
$3.7B , more than double the next largest vertical (legal). This domain-specific spend is50% of healthcare organizations' AI spend, more than 2x the average enterprise. - AI for drug discovery is breaking out: Spend jumped from
$30M to$700M (23x) as pharma deploys AI at scale. - The provider market is evolving rapidly as incumbents strike back. Microsoft and Epic took
68% of new scribing dollars, while early scribes are extending into new categories. - AI innovation is moving closer to the patient. Clinical copilots grew 5.5x to
$550M and patient engagement 4.5x to$450M , versus 1.3x for coding and billing. - Payers are paying for providers' AI, not their own. Payer AI spend lags (19x less vs. providers), while
43% say provider AI coding has increased their costs.
There are currently 5,724,857 common shares of DataMEDS outstanding, including 2,745,900 common shares deposited in Depository Trust & Clearing Corporation (DTCC) available for trading. Certain stockholders holding approximately 1,333,930 common shares have entered into lock-up agreements that preclude the sale of their shares into the market for at least ninety (90) days from today's date. There are no debt, preferred equity or warrant securities of the Company that are eligible to convert into free trading common shares as of the date of this press release. There is a total of 80,826 cash warrants outstanding, each with a fixed exercise price of
About DataMEDS AI
DataMEDS AI, Inc. (NASDAQ:MEDS), formerly Wellgistics Health, Inc., is a healthcare company focused on the vertical integration of technology, pharmacy, pharmaceutical-adjacent and telemedicine business units through its health information technology platforms to deliver a better experience for consumers and providers. Headquartered in Tampa, Fla., DataMEDS incorporates its EinsteinRx™ artificial intelligence platform and PharmacyChain™ blockchain-enabled smart contracts platform into the Health Lives Here mobile application from Tollo Health, LLC, and its pharmacy-related Corexa Health subsidiary provides pharmacy dispensing and pharmacy-related services, including distribution of products developed by Tollo Health. DataMEDS also owns Helomics Corporation, a Pittsburgh, PA-based commercial clinical molecular diagnostics laboratory focused on the ChemoFx® Assay chemotherapy selection diagnostics test that aims to help oncologists make chemotherapy treatment decisions. Learn more at https://datamedsai.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are not predictions of actual performance. Forward-looking statements include, without limitation, statements regarding: the Company's ability to complete its operational turnaround and achieve profitability; the Company's business strategy, including its ability to integrate its pharmacy, laboratory, telemedicine and data platforms and generate synergistic revenue; the success of the Health Lives Here initiative and the Company's GLP-1 patient management programs, including its arrangement with a health maintenance organization and its ability to demonstrate improved outcomes or lower costs and attract additional institutional payors; sales of medical food and other support products, and the Company's ability to use related patient data for research; the integration of Helomics and its ability to establish biopharmaceutical and artificial intelligence research partnerships and participate in resulting intellectual property; the size and continued growth of the Helomics biobank, and the scope of patient consents and IRB approvals governing research use of samples and data; patients' willingness to permit use of their de-identified data; compliance with healthcare, data privacy, security, FDA and FTC requirements; competition; and the Company's liquidity, capital resources and ability to fund operations. Actual results may differ materially from those expressed or implied in these forward-looking statements due to a number of risks and uncertainties, including those described under "Risk Factors" in the Company's most recent Annual Report on Form 10-K and subsequent filings with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to update or revise any forward-looking statements, except as required by law.
DataMEDS AI Media Contact
James Lambert, Vice President, Rubenstein Public Relations
212.805.3024 | jlambert@rubensteinpr.com
DataMEDS AI Investor Contact
IR@datamedsai.com
###
SOURCE: DataMEDS AI, Inc.
View the original press release on ACCESS Newswire
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What are DataMEDS AI's priorities in its fourth-quarter 2026 CEO letter?
DataMEDS plans to combine patient care operations and healthcare data to support GLP-1 patient management, research and new intellectual property. The company aims to improve outcomes and reduce costs through its pharmacy, laboratory and telemedicine operations.